Abstract
Several treatment options are being explored to reduce the transfusion burden and improve quality of life for patients with beta-thalassemia. One such prospect is the drug luspatercept, which has recently been approved for use in the USA for the treatment of beta-thalassemia. However, socioeconomic factors may act as a barrier to its widespread use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 16-17 |
| Number of pages | 2 |
| Journal | European Oncology and Haematology |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2020 |
Keywords
- Beta-thalassemia
- Cooley’s anaemia
- Luspatercept
- Microcytaemia
- Thalassemia
- Thalassemia major
ASJC Scopus subject areas
- Hematology
- Oncology